<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652481</url>
  </required_header>
  <id_info>
    <org_study_id>C1734</org_study_id>
    <nct_id>NCT02652481</nct_id>
  </id_info>
  <brief_title>ENABLE MRI (Magnetic Resonance Imaging)</brief_title>
  <acronym>ENABLE-MRI</acronym>
  <official_title>Expanding MRI (Magnetic Resonance Imaging) Access for Patients With New and Existing ICDs (Implantable Cardioverter Defibrillator) and CRT-Ds (Cardiac Resynchronization Therapy Defibrillator)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect data to confirm the safety and effectiveness of the
      Image Ready™ MR (Magnetic Resonance) Conditional Defibrillation System when used in the 1.5T
      (Tesla) MRI environment under the labeled Conditions of Use (Phase I).

      Additionally, the study will assess medically necessary MR scans according to the labeled
      Conditions of Use to provide real-world scanning data (Phase I and Phase II).The study also
      aims to demonstrate the continued ability of the ImageReady MR Conditional Defibrillation
      System to sense and detect ventricular fibrillation (VF) post MRI scan by collecting and
      analyzing data from spontaneous VF episodes, &quot;for-cause&quot; VF inductions, and from an optional
      VF induction Sub-study.

      .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 4, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Free From MR (Magnetic Resonance) Scan-related Complications</measure>
    <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
    <description>MR scan-related CFR (Complication-free rate) between the MR Scan and the MRI + 1 (Magnetic Resonance Imaging) Month Visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants That Had an Increase in Average Pacing Thresholds ≤ 0.5V (Volt) (at 0.5 ms) in the RV</measure>
    <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
    <description>Increases in RV pacing threshold (at 0.5 ms) pre- MR scan and 1 Month post-MR scan were calculated for subjects. Subjects that had an increase in average pacing thresholds ≤ 0.5V (at 0.5 ms) from pre-MR Scan to MRI Visit + 1 Month follow-up were considered a success.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants That Had an Increase in Average LV ( Left Ventricle) Pacing Threshold ≤ 1.0V (Volt) at 0.5 ms.</measure>
    <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
    <description>Increases in average LV pacing threshold (at 0.5 ms) pre- MR scan and 1 Month post-MR scan were calculated for subjects. Subjects that had an increase in pacing thresholds measurements ≤ 1.0V (at 0.5 ms) from pre-MR Scan at MRI Visit to MRI + 1 Month Visit were considered a success.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants That Had a Decrease in RV ( Right Ventricle) Sensed Amplitude</measure>
    <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
    <description>Decreases in RV sensed amplitude pre-MR scan and 1 Month post-MR scan were calculated for subjects. Subjects were considered a success if the average sensed amplitude at the MRI + 1 Month Visit remains ≥ 5.0 mV and above 50% of the pre-MR scan value. Subjects who had an average pre-scan RV sensed amplitude measurement &lt; 5.0 mV were excluded from this analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants That Decrease in LV ( Left Ventricle) Sensed Amplitude</measure>
    <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
    <description>Decreases in average LV sensed amplitude pre-MR scan and 1 Month post-MR scan were calculated for subjects. Subjects were considered a success if the average sensed amplitude at the MRI + 1 Month Visit remained ≥ 5.0 mV and above 50% of the average pre-MR scan value. Subjects who had an average pre-scan LV sensed amplitude measurement &lt; 5.0 mV were excluded from this analysis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>ImageReady MR Conditional Defibrillation System Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).
De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ImageReady MR Conditional Defibrillation System</intervention_name>
    <description>ImageReady MR Conditional Defibrillation System Components:
Device Name Device Model Number Pulse Generators Phase I and II Phase II Only * CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads
* May only be used internationally outside the US</description>
    <arm_group_label>ImageReady MR Conditional Defibrillation System Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Phase I: Subject is indicated per guidelines and will receive a CRT-D or ICD system OR
             Subject is implanted with a functional and stable CRT-D or ICD system Phase II:
             Subject is implanted with a functional and stable CRT-D or ICD system

          2. Subject will receive or is implanted with an ICD or CRT-D pulse generator in the left
             or right pectoral region

          3. Subject is able and willing to undergo an MR scan without intravenous sedation (Phase
             I only)

          4. Subject is willing and capable of providing informed consent and participating in all
             testing/ visits associated with this clinical study at an approved clinical study
             center and at the intervals defined by this protocol

          5. Subject is age 18 or above, or of legal age to give informed consent specific to state
             and national law

        Key Exclusion Criteria:

          1. Subject implanted with an ICD or CRT-D pulse generator with battery at Explant status

          2. Subject has other active or abandoned implanted cardiac rhythm devices, components or
             accessories present such as pulse generators, leads, lead adaptors or extenders

          3. Presence of metallic objects that represent a contraindication to MR imaging at the
             discretion of the Radiologist and impacting the ability to conduct the study protocol

          4. Subject needs or will need a medically necessary MR scan, before completing the
             1-month post-MR follow-up visit (Phase I only)

          5. Subject with:

               -  A history of syncope related to brady-arrhythmia

               -  A history of syncope of unknown etiology

               -  Sinus pauses (Pause &gt; 2 s)

               -  Permanent or intermittent complete AV (Atrioventricular ) block

               -  Documentation of progressive AV nodal block over time

               -  Trifascicular block (alternating bundle branch block or PR &gt; 200 ms (interval
                  between P wave and R-wave) with LBBB ( Left bundle branch block) or other
                  bifascicular block) Note: It is required to run a 12 lead ECG
                  (Electrocardiography) and a 10s rhythm strip to document this exclusion
                  criterion. During ECG acquisition, subjects must be in either their own intrinsic
                  rhythm or, in subjects with an existing device implant, the device must be
                  programmed to VVI (ventricular demand pacing) 40 ppm.

          6. Subject is not clinically capable of tolerating the absence of pacing or
             Resynchronization therapy support in a supine position for the duration that the pulse
             generator is in MRI Protection Mode, per Physician discretion

          7. Subject is not clinically capable of tolerating the absence of Tachycardia therapy
             support for the duration that the pulse generator is in MRI Protection Mode, per
             Physician discretion

          8. Subjects with a planned RA( right atrium), RV ( right ventricle) or LV (left
             ventricle) lead revision or extraction within 30 days of enrollment (Phase I only)

          9. Subjects with an implanted lead that is planned to be extracted during the study
             implant procedure

         10. Subjects currently requiring dialysis

         11. Subject has a mechanical heart valve

         12. Subject has a known or suspected sensitivity to dexamethasone acetate (DXA)

         13. Subject is currently on the active heart transplant list

         14. Subject has documented life expectancy of less than 12 months

         15. Subject is enrolled in a concurrent study, with the exception of local mandatory
             governmental registries and observational studies/registries, without the written
             approval from Boston Scientific

         16. Women of childbearing potential who are or might be pregnant, and will receive an ICD
             or CRT-D pulse generator

        VF Induction Sub-study Exclusion Criteria:

        In addition to meeting all of the inclusion criteria and none of the exclusion criteria of
        the ENABLE MRI study, subjects enrolled in the VF Induction Sub-study must also not meet
        any of the following VF Induction Sub-study exclusion criteria:

          1. Unstable heart failure requiring hospitalization in the last 30 calendar days

          2. Unable to tolerate sedation (e.g. IV (intravenous sedation )sedation, general
             anesthesia)

          3. Planned cardiac revascularization procedure

          4. Right Ventricular Lead R wave is less than 5 mV(milliVolt)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Voss</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Northeast Arkansas</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Memorial Hospital</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego-N</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Center</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manatee Memorial Hospital</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Medical Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Community Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marquette General Hospital</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centracare Heart and Vascular Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cox Health</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research and Innovation Institute - Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Medical Specialists</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Research Institute, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SouthEast Texas Clinical Research Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston Health Science Center</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Mother Frances Health System</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center Everett</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Southwest Medical</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover MHH</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka MC</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Hebrew University Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione di Ricerca e Cura 'Giovanni Paolo II'</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo-Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.G. Calibita Fatebenefratelli - Isola Tiberina</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale san giovanni calibita</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Casilino</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Maria Della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys and St. Thomas NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Palau</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <results_first_submitted>June 7, 2018</results_first_submitted>
  <results_first_submitted_qc>June 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2019</results_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02652481/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ImageReady MR Conditional Defibrillation System Group</title>
          <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the “MRI protection mode”. This new MRI scan feature was considered “investigational” , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects enrolled into Phase I and underwent a required (non-diagnostic, non-medically necessary) MRI. The data from phase I (N=237) was used for the PMA application and approval. Enrollment was stopped for phase II once 500 enrolled subjects were reached. Baseline participants are 498 patients as two patients were enrolled in error.</population>
      <group_list>
        <group group_id="B1">
          <title>ImageReady™ MR Conditional Defibrillation System</title>
          <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the “MRI protection mode”. This new MRI scan feature was considered “investigational” , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="498"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="381"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Free From MR (Magnetic Resonance) Scan-related Complications</title>
        <description>MR scan-related CFR (Complication-free rate) between the MR Scan and the MRI + 1 (Magnetic Resonance Imaging) Month Visit</description>
        <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
        <population>All implanted subjects that completed any portion of the study required MR scan and did not have a Medically Necessary Scan (MNS) performed prior to the MRI+1 Month Visit were included in the Primary Safety Endpoint analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>ImageReady MR Conditional Defibrillation System Group</title>
            <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the &quot;MRI protection mode&quot;. This new MRI scan feature was considered &quot;investigational&quot; , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free From MR (Magnetic Resonance) Scan-related Complications</title>
          <description>MR scan-related CFR (Complication-free rate) between the MR Scan and the MRI + 1 (Magnetic Resonance Imaging) Month Visit</description>
          <population>All implanted subjects that completed any portion of the study required MR scan and did not have a Medically Necessary Scan (MNS) performed prior to the MRI+1 Month Visit were included in the Primary Safety Endpoint analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Had an Increase in Average Pacing Thresholds ≤ 0.5V (Volt) (at 0.5 ms) in the RV</title>
        <description>Increases in RV pacing threshold (at 0.5 ms) pre- MR scan and 1 Month post-MR scan were calculated for subjects. Subjects that had an increase in average pacing thresholds ≤ 0.5V (at 0.5 ms) from pre-MR Scan to MRI Visit + 1 Month follow-up were considered a success.</description>
        <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
        <population>Did not include subjects that had a MNS between implant and the MRI+1Month Visit; Failed to meet Conditions of Use; Experienced lead-related complication; Had an incomplete scan or no scan, died or withdrew consent, missed a visit, missed lead measurements</population>
        <group_list>
          <group group_id="O1">
            <title>ImageReady MR Conditional Defibrillation System Group</title>
            <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the &quot;MRI protection mode&quot;. This new MRI scan feature was considered &quot;investigational&quot; , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Had an Increase in Average Pacing Thresholds ≤ 0.5V (Volt) (at 0.5 ms) in the RV</title>
          <description>Increases in RV pacing threshold (at 0.5 ms) pre- MR scan and 1 Month post-MR scan were calculated for subjects. Subjects that had an increase in average pacing thresholds ≤ 0.5V (at 0.5 ms) from pre-MR Scan to MRI Visit + 1 Month follow-up were considered a success.</description>
          <population>Did not include subjects that had a MNS between implant and the MRI+1Month Visit; Failed to meet Conditions of Use; Experienced lead-related complication; Had an incomplete scan or no scan, died or withdrew consent, missed a visit, missed lead measurements</population>
          <units>percentage of participants with success</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.32" lower_limit="96.79" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Had an Increase in Average LV ( Left Ventricle) Pacing Threshold ≤ 1.0V (Volt) at 0.5 ms.</title>
        <description>Increases in average LV pacing threshold (at 0.5 ms) pre- MR scan and 1 Month post-MR scan were calculated for subjects. Subjects that had an increase in pacing thresholds measurements ≤ 1.0V (at 0.5 ms) from pre-MR Scan at MRI Visit to MRI + 1 Month Visit were considered a success.</description>
        <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
        <population>did not include subjects with a MNS between implant and the MRI + 1 Month Visit;failed to meet labeled MRI Conditions of Use, had lead-related complication;had an incomplete scan or no scan; missing lead measurements; missed a visits, subject died or withdrew consent</population>
        <group_list>
          <group group_id="O1">
            <title>ImageReady MR Conditional Defibrillation System Group</title>
            <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the &quot;MRI protection mode&quot;. This new MRI scan feature was considered &quot;investigational&quot; , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Had an Increase in Average LV ( Left Ventricle) Pacing Threshold ≤ 1.0V (Volt) at 0.5 ms.</title>
          <description>Increases in average LV pacing threshold (at 0.5 ms) pre- MR scan and 1 Month post-MR scan were calculated for subjects. Subjects that had an increase in pacing thresholds measurements ≤ 1.0V (at 0.5 ms) from pre-MR Scan at MRI Visit to MRI + 1 Month Visit were considered a success.</description>
          <population>did not include subjects with a MNS between implant and the MRI + 1 Month Visit;failed to meet labeled MRI Conditions of Use, had lead-related complication;had an incomplete scan or no scan; missing lead measurements; missed a visits, subject died or withdrew consent</population>
          <units>percentage of participants with succes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.53" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Had a Decrease in RV ( Right Ventricle) Sensed Amplitude</title>
        <description>Decreases in RV sensed amplitude pre-MR scan and 1 Month post-MR scan were calculated for subjects. Subjects were considered a success if the average sensed amplitude at the MRI + 1 Month Visit remains ≥ 5.0 mV and above 50% of the pre-MR scan value. Subjects who had an average pre-scan RV sensed amplitude measurement &lt; 5.0 mV were excluded from this analysis.</description>
        <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
        <population>Did not include subjects that had a MNS between implant and the MRI+1Month Visit; Failed to meet Conditions of Use; Experienced lead-related complication; Had an incomplete scan or no scan, died or withdrew consent, missed a visit, missed lead measurements; had an average pre-scan RV sensed amplitude measurement &lt; 5.0 mV.</population>
        <group_list>
          <group group_id="O1">
            <title>ImageReady MR Conditional Defibrillation System Group</title>
            <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the &quot;MRI protection mode&quot;. This new MRI scan feature was considered &quot;investigational&quot; , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Had a Decrease in RV ( Right Ventricle) Sensed Amplitude</title>
          <description>Decreases in RV sensed amplitude pre-MR scan and 1 Month post-MR scan were calculated for subjects. Subjects were considered a success if the average sensed amplitude at the MRI + 1 Month Visit remains ≥ 5.0 mV and above 50% of the pre-MR scan value. Subjects who had an average pre-scan RV sensed amplitude measurement &lt; 5.0 mV were excluded from this analysis.</description>
          <population>Did not include subjects that had a MNS between implant and the MRI+1Month Visit; Failed to meet Conditions of Use; Experienced lead-related complication; Had an incomplete scan or no scan, died or withdrew consent, missed a visit, missed lead measurements; had an average pre-scan RV sensed amplitude measurement &lt; 5.0 mV.</population>
          <units>percentage of participants with succes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.32" lower_limit="96.79" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Decrease in LV ( Left Ventricle) Sensed Amplitude</title>
        <description>Decreases in average LV sensed amplitude pre-MR scan and 1 Month post-MR scan were calculated for subjects. Subjects were considered a success if the average sensed amplitude at the MRI + 1 Month Visit remained ≥ 5.0 mV and above 50% of the average pre-MR scan value. Subjects who had an average pre-scan LV sensed amplitude measurement &lt; 5.0 mV were excluded from this analysis.</description>
        <time_frame>The time between the MR Scan and MRI + 1 Month</time_frame>
        <population>did not include subjects with a MNS between implant and the MRI + 1 Month Visit;failed to meet labeled MRI Conditions of Use, had lead-related complication;had an incomplete scan or no scan; missing lead measurements; missed a visits, subject died or withdrew consent; Average LV sensed amplitude &lt;5mV (3 patients)</population>
        <group_list>
          <group group_id="O1">
            <title>ImageReady MR Conditional Defibrillation System Group</title>
            <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the &quot;MRI protection mode&quot;. This new MRI scan feature was considered &quot;investigational&quot; , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Decrease in LV ( Left Ventricle) Sensed Amplitude</title>
          <description>Decreases in average LV sensed amplitude pre-MR scan and 1 Month post-MR scan were calculated for subjects. Subjects were considered a success if the average sensed amplitude at the MRI + 1 Month Visit remained ≥ 5.0 mV and above 50% of the average pre-MR scan value. Subjects who had an average pre-scan LV sensed amplitude measurement &lt; 5.0 mV were excluded from this analysis.</description>
          <population>did not include subjects with a MNS between implant and the MRI + 1 Month Visit;failed to meet labeled MRI Conditions of Use, had lead-related complication;had an incomplete scan or no scan; missing lead measurements; missed a visits, subject died or withdrew consent; Average LV sensed amplitude &lt;5mV (3 patients)</population>
          <units>percentage of participants with succes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.31" lower_limit="94.76" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety data are presented for subjects as from enrollment until study completion ( 4 May 2018)</time_frame>
      <desc>Investigators were asked to classify whether an adverse event was considered serious or nonserious,whether it was anticipated or unanticipated; met USADE(Unanticipated Serious Adverse Device Effect); UADE (Unanticipated Adverse Device Effect) definition and whether it was device or procedure related. All reportable events experienced by the study subject after giving informed consent were to be reported. Two patients were enrolled in error and three patients were withdrawn (intent); 495 at risk</desc>
      <group_list>
        <group group_id="E1">
          <title>ImageReady MR Conditional Defibrillation System Group</title>
          <description>This is a prospective, non-randomized, confirmatory study. Some defibrillator systems are not able to be used with MRI scanners because the material they are made out. Boston Scientific has a defibrillation system with a new feature that blocks interference from an MRI scanner when the defibrillator system is set to the &quot;MRI protection mode&quot;. This new MRI scan feature was considered &quot;investigational&quot; , meaning was investigated because it was not approved by the US Food and Drug Administration (FDA) for patient use. This new defibrillation system is called the ImageReady Defibrillation System. Together, the defibrillator and the lead(s) are called the ImageReady System. The ImageReady system is considered investigational in the US because not all the component parts are approved by the FDA. Patients who have a ImageReady defibrillator will undergo an MRI and data will be collected. Periodic checks were planned to check the defibrillator system</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Abnormal laboratory values</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Peripheral edema - Heart failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypotension - Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation (VF)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia (VT)/Monomorphic VT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Nonsustained Ventricular Tachycardia (NSVT)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation (AF)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia/Other SVT (eg AVRT, AVNRT, EAT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Atrial (Type I) Flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypotension/Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypertension/Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Chest pain - Ischemic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Myocardial perforation with tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Chest pain - Heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pulmonary edema - Heart failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Renal insufficiency/failure - Heart failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dehydration - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Mitral regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Valvular damage/Valvular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack (TIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident (CVA)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Incessant VT/VT Storm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Multi-system failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (&gt;30 days post-implant) - PG System - Subject related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Fever and/or Virus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post-surgical wound discomfort/bruising/swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Respiratory - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&lt;=30 days post-implant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pericardial effusion - Procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Venous occlusion - Procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Other - PG system procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Anesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Medication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Unable to capture - LV PG System</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - LV PG System</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Inappropriate Tachy Therapy - SVT - PG System Therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pacemaker Mediated Tachycardia - PG System Therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated threshold -RV Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - Multiple signs - RV Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - RV Lead</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - LV Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Unable to capture - RV Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Conductor coil fracture - RA Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Migration - PG System - Subject related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Localized Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction - Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Abnormal laboratory values</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Peripheral edema - Heart failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypotension - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Multiple heart failure symptoms</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation (VF)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia (VT)/Monomorphic VT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Nonsustained Ventricular Tachycardia (NSVT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation (AF)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia/Other SVT (eg AVRT, AVNRT, EAT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Atrial (Type I) Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypotension/Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypertension/Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Chest pain - Ischemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Chest pain - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Syncope - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypertension - Heart failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Premature Ventricular Contractions (PVC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pericardial effusion - Unrelated (non study) procedure or device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Multi-system failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (&gt;30 days post-implant) - PG System - Subject related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>HEENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post-surgical wound discomfort/bruising/swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Respiratory - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&lt;=30 days post-implant)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pericardial effusion - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Venous occlusion - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Other - PG system procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Anesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Adverse reaction - Medication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Unable to capture - LV PG System</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - LV PG System</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Inappropriate Tachy Therapy - SVT - PG System Therapy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pacemaker Mediated Tachycardia - PG System Therapy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated threshold -RV Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - Multiple signs - RV Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - RV Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dislodgment - No reported signs - LV Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Elevated threshold - LV PG System</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>pain at device site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Conductor coil fracture - RA Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - RV Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Psychological effect due to device therapy - PG System - Subject related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Physical trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Localized Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction - Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Distal thromboemboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Manager</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>+32479983495</phone>
      <email>anneleen.viville@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

